Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.

Autor: Tullman M; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France. mjt2796@bjc.org., Chartier-Kastler E; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Kohan A; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Keppenne V; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Brucker BM; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Egerdie B; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Mandle M; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Nicandro JP; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Jenkins B; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France., Denys P; From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France.

Publikováno v: Neurology [Neurology] 2018 Aug 14; Vol. 91 (7), pp. e657-e665. Date of Electronic Publication: 2018 Jul 20.

The Effect of Ondansetron on Improvement of Symptoms in Patients with Irritable Bowel Syndrome with Diarrhea Domination: A Randomized Controlled Trial.

Autor: Jafari, Sattar¹, Atmani, Arezoo², Gohari, Sepehr^3,4 Sepehr_goharibdb@yahoo.com, Seifi, Ehsan³

Publikováno v: Middle East Journal of Digestive Diseases. Jul2024, Vol. 16 Issue 3, p178-184. 7p.

Evaluation of treatment continuation with alosetron by IBS-D severity criteria.

Autor: Nicandro JP, Shin P, Chuang E

Publikováno v: Current Medical Research & Opinion; 2012 Mar, Vol. 28 Issue 3, p449-456, 8p

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

Autor: Cremonini F; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA02215, USA. fcremoni@bidmc.harvard.edu, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2012 Sep; Vol. 36 (5), pp. 437-48. Date of Electronic Publication: 2012 Jul 10.

In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4.

Autor: Nicandro JP; Dept of Clinical Pharmacy, University of California, San Francisco, CA 94143, USA. ps01459@itsa.ucsf.edu, Tsourounis C, Frassetto L, Guglielmo BJ

Publikováno v: Journal of herbal pharmacotherapy [J Herb Pharmacother] 2007; Vol. 7 (1), pp. 39-56.